A case of palmar hypopigmentation induced by capecitabine in a gastrointestinal cancer patient.
Fiche publication
Date publication
juillet 2021
Journal
Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners
Auteurs
Membres identifiés du Cancéropôle Est :
Pr BOUCHE Olivier
Tous les auteurs :
Gratiaux J, Gossery C, Rezzag-Mahcene C, Botsen D, Visseaux L, Slimano F, Bouche O
Lien Pubmed
Résumé
Capecitabine is an antimetabolite antineoplastic agent widely used in the treatment gastrointestinal cancers. The common frequently reported cutaneous adverse drug reaction associated with capecitabin are a palmar-plantar erythrodysesthesia syndrome, rash and hyperpigmentation. This case reports a capecitabine-induced palmar hypopigmentation.
Mots clés
Capecitabine/fluorouracil/adverse effects, antimetabolites, antineoplastic/pigmentation disorders/vitiligo
Référence
J Oncol Pharm Pract. 2021 Jul 7;:10781552211027936